Bacterial meningitis: the impact of vaccination.
Acute bacterial meningitis remains an important cause of morbidity and mortality in children. Children <2 years of age are particularly susceptible to infection with encapsulated bacteria due to their immature response to polysaccharide antigens. Conjugate vaccines, which induce T cell memory, can provide immunological protection for these children. The Haemophilus influenzae type b (Hib) conjugate vaccine was the first such vaccine to become available. The efficacy of the vaccine has been quoted as being 98%. Its introduction was followed by a dramatic decrease in the incidence of all invasive Hib disease, including meningitis. This reduction was in part due to the ability of these vaccines to reduce nasopharyngeal carriage of the organism and thereby induce herd immunity. Different Hib vaccines use a variety of protein carriers and differ in their immunogenicity and efficacy. The most suitable vaccine needs to be determined according to the local epidemiology of Hib disease. Commercial combination vaccines may lead to lower antibody levels. A recent increase in the incidence of Hib disease in the UK highlights the importance of continued surveillance and the need for booster vaccinations to ensure continued protection. Conjugate vaccines to Streptococcus pneumoniae and Neisseria meningitidis have been developed. The introduction of a pneumococcal conjugate vaccine in the US has led to a decrease in the rate of infection by nearly 60% in children <5 years of age. A reduction in pneumococcal carriage may also modify disease epidemiology. The UK introduced the conjugate meningococcal C vaccine into its infant schedule with a corresponding reduction in N. meningitidis group C disease. A recent decrease in the effectiveness of the vaccine, however, suggests a booster may be necessary in the future. Our present understanding of the immunology of conjugate vaccines is far from complete. Developed countries have introduced conjugate vaccines into their immunisation schedules to prevent bacterial meningitis; however, their high cost precludes their use in many developing countries. Progress needs to be made in order to get these highly effective vaccines to those areas that need them.
Makwana
Nick
N
Department of Child Health, Royal Liverpool Childrens Hospital, Liverpool, England.
Riordan
F Andrew I
FA
D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D018073:Haemophilus Vaccines / Q000627:therapeutic use; D006801:Humans; D016920:Meningitis, Bacterial / Q000453:epidemiology / Q000517:prevention & control*; D008583:Meningitis, Haemophilus / Q000517:prevention & control; D008585:Meningitis, Meningococcal / Q000517:prevention & control; D008586:Meningitis, Pneumococcal / Q000517:prevention & control; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000627:therapeutic use
D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D018074:Vaccines, Conjugate